A new study in the Journal of Infection by Dr. Tristan Clark, et al. titled “Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19” identifies the FebriDx® test as a rapid, highly accurate, and affordable ‘front door triage tool’ to help healthcare providers differentiate viral from bacterial infection in patients with suspected COVID-19. In this study of 251 patients, FebriDx showed high diagnostic accuracy and speed for identifying a viral infection when compared to PCR for confirming COVID-19.
- Click here to access the study.
SEE ALSO
October 6, 2020
Lumos Diagnostics raises AU$25m in oversubscribed pre-IPO capital raise
Lumos Diagnostics has closed an oversubscribed AU$25 million pre-IPO capital raise, ahead of an anticipated 2021 Australian Securities Exchange (ASX) listing.